Evaluation of ⁶⁴Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates.

ABSTRACT:

Objectives

To improve the prognosis of pancreatic cancer, new imaging methods to identify tumor lesions at a size of <1 cm are urgently needed. To approach this clinical issue, we developed a new method to detect small tumor lesions in the pancreas (≥3 mm) by positron emission tomography (PET) using an intraperitoneally (ip)-administered ⁶⁴Cu-labeled new anti-epidermal growth factor receptor (EGFR) antibody (encoded as NCAB001), called ⁶⁴Cu-NCAB001 ipPET.

Methods

NCAB001 was manufactured under cGMP conditions and labeled with ⁶⁴Cu. The radiochemical and biological properties of ⁶⁴Cu-NCAB001 were evaluated. Tumor uptake of an ip-administered ⁶⁴Cu-NCAB001 in mice with orthotopic pancreatic tumor xPA1-DC xenografts was also

SUBMITTER: Matsumoto H 

PROVIDER: S-EPMC8540406 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature